Review the side-effects of Bromfenac Ophthalmic Solution as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication.

Discover comprehensive details about Bromfenac Ophthalmic Solution, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The ...

Ask a clinical question and tap into Healio AI's knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio's exclusive daily news coverage of ...

Bromfenac Ophthalmic Solution, 0.075 per cent is the generic equivalent of BromSite Ophthalmic Solution, 0.075 per cent, of Sun Pharmaceutical Industries Limited. It is indicated for the treatment of ...

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic Bromfenac ophthalmic solution, which is indicated for the treatment of ...

Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who ...

Intraocular neovascularization is the leading cause of severe visual loss and anti-vascular endothelial growth factor (VEGF) therapy is currently performed for choroidal neovascularization (CNV).

Alembic Pharmaceuticals Ltd announced on Tuesday that it has received final approval from the US Food & Drug Administration (USFDA) for its generic Bromfenac ophthalmic solution. This approval is for ...

Company announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA(TM) (bromfenac ophthalmic solution), ISTA's once-daily topical ...

IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) , today announced positive results from a proof-of-concept Phase 2 clinical ...

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering ...